The cannabis telemedicine industry, namely the flood of online healthcare businesses offering prescriptions virtually across global medical cannabis markets, has provided the greatest boom to the industry since the ‘green rush’ of 2018 in recent years.
Now, however, governments and medical associations are pushing back against this rapid growth in collective moves that could see some of the world’s fastest growing markets significantly restricted.
Germany’s Ministry of Health has now published a long-feared draft amendment to its Medical Cannabis Act (MedCanG), threatening a crackdown which will be a major cause for concern for hundreds of cannabis businesses, both in and outside of German borders.
In parallel, the thriving Australian market is also enduring a widespread crackdown after the Australian Health Practitioner Regulation Agency (AHPRA) issued new guidance, specifically targeting ‘direct-to-consumer, single-issue telehealth models’.
Back in May new figures showed that German medical cannabis imports have continued their meteoric rise, growing a further 15% on Q4, 2024 in the first quarter of 2025, totalling 37,223 kg.
In the wake of these dizzying growth statistics, the newly sworn in Federal Minister of Health, Nina Warken (CDU) seized the initiative and told Frankfurter Allgemeine Zeitung (FAZ) that she wants to ‘restrict the easily accessible online prescriptions’.
While this has long been a talking point of the anti-cannabis CDU party, their recent election success, seeing them become the largest party in the Bundestag (though not large enough to form a government alone), signalled that this rhetoric could soon become real-world policy.
This week, the German Federal Ministry of Health confirmed these fears, publishing a draft amendment targeting the loosely regulated telemedicine market in Germany.
According to the Ministry, imports of medical cannabis flowers rose by 170% between the first and second halves of 2024, while (statutory health insurance) GKV-covered prescriptions increased by just 9%.
This, they say, suggests that a significant share of products are reaching patients via private prescriptions, often facilitated by online platforms with no in-person medical evaluation. The Ministry argued that this trend undermines patient safety, given that cannabis flowers are unlicensed medicines with addiction potential and cognitive health risks.
As such, it proposes the following changes to the MedCanG law:
In-person consultations now mandatory
Ban on Mail-Order Dispensing
Legal Sanctions for Non-Compliance
The bill must now be approved by the Federal Cabinet, led by Chancellor Friedrich Merz and including ministers from the CDU/CSU–SPD coalition.
Given that the SPD were the original architects of the bill, it is unclear whether they will vote to approve the draft as it stands.
According to Prohibition Partners’ Global Cannabis Report: 5th Edition, Australia’s medical cannabis revenues are expected to grow from around US$600m in 2024 to more than US$1.2bn by 2028.
For comparison, this is over half of the projected value of all medical cannabis sales in Europe by 2028 (US$2.2 billion by 2028), with Germany’s sales accounting for US$1.2bn alone.
With growth rates fast catching up to the more mature German market, similarly driven by the explosion of telehealth services, Australian authorities have also raised concerns about the lack of oversight and potential for abuse of this model.
In September 2024, the Australian Health Practitioner Regulation Agency (AHPRA) established a new Rapid Regulatory Response Unit (RRRU), tasked with investigating rapidly evolving healthcare models, including online prescriptions for medical cannabis.
This marked a stark shift in its strategy, moving from targeting individual practitioners to investigating systemic issues in its current framework.
Earlier this month, new prescribing data gathered by the regulator uncovered what it called concerning prescribing patterns, raising ‘red flags’ and showing that ‘some practitioners are not meeting their professional obligations’.
This included findings that just eight practitioners had issued more than 10,000 prescriptions over a six-month period, including a single prescriber who issued over 17,000 by themselves.
In response, AHPRA has published new guidance for the medical cannabis sector, warning operators that it will not hesitate to prosecute those who violate these new rules.
AHPRA has already taken action against 57 healthcare practitioners, and is investigating a further 60.
The new AHPRA guidelines require clinics to:
The post Victim of Its Own Success?: German & Australian Regulators Crackdown on Booming Cannabis Telemedicine Sector appeared first on Business of Cannabis.
Continue reading...
Now, however, governments and medical associations are pushing back against this rapid growth in collective moves that could see some of the world’s fastest growing markets significantly restricted.
Germany’s Ministry of Health has now published a long-feared draft amendment to its Medical Cannabis Act (MedCanG), threatening a crackdown which will be a major cause for concern for hundreds of cannabis businesses, both in and outside of German borders.
In parallel, the thriving Australian market is also enduring a widespread crackdown after the Australian Health Practitioner Regulation Agency (AHPRA) issued new guidance, specifically targeting ‘direct-to-consumer, single-issue telehealth models’.
Germany
Back in May new figures showed that German medical cannabis imports have continued their meteoric rise, growing a further 15% on Q4, 2024 in the first quarter of 2025, totalling 37,223 kg.
In the wake of these dizzying growth statistics, the newly sworn in Federal Minister of Health, Nina Warken (CDU) seized the initiative and told Frankfurter Allgemeine Zeitung (FAZ) that she wants to ‘restrict the easily accessible online prescriptions’.
While this has long been a talking point of the anti-cannabis CDU party, their recent election success, seeing them become the largest party in the Bundestag (though not large enough to form a government alone), signalled that this rhetoric could soon become real-world policy.
This week, the German Federal Ministry of Health confirmed these fears, publishing a draft amendment targeting the loosely regulated telemedicine market in Germany.
According to the Ministry, imports of medical cannabis flowers rose by 170% between the first and second halves of 2024, while (statutory health insurance) GKV-covered prescriptions increased by just 9%.
This, they say, suggests that a significant share of products are reaching patients via private prescriptions, often facilitated by online platforms with no in-person medical evaluation. The Ministry argued that this trend undermines patient safety, given that cannabis flowers are unlicensed medicines with addiction potential and cognitive health risks.
As such, it proposes the following changes to the MedCanG law:
In-person consultations now mandatory
Initial prescriptions for cannabis flowers must follow a face-to-face consultation (in practice or via a home visit)
Follow-up prescriptions online will still be allowed, but only if a personal consultation occurred in the past 12 months (4 quarters)
Ban on Mail-Order Dispensing
Shipping of cannabis flowers directly to patients will no longer be allowed
During the in-person consultation, patients must provide detailed medical history, alongside a physical examination and explicit consent to be treated with medical cannabis flower
Prescriptions must now be collected in person at a pharmacy
This is designed to ensure proper pharmaceutical counselling on use, side effects, and storage
Legal Sanctions for Non-Compliance
Violations of these new rules would incur legal sanctions under MedCanG
The bill must now be approved by the Federal Cabinet, led by Chancellor Friedrich Merz and including ministers from the CDU/CSU–SPD coalition.
Given that the SPD were the original architects of the bill, it is unclear whether they will vote to approve the draft as it stands.
Australia
According to Prohibition Partners’ Global Cannabis Report: 5th Edition, Australia’s medical cannabis revenues are expected to grow from around US$600m in 2024 to more than US$1.2bn by 2028.
For comparison, this is over half of the projected value of all medical cannabis sales in Europe by 2028 (US$2.2 billion by 2028), with Germany’s sales accounting for US$1.2bn alone.
With growth rates fast catching up to the more mature German market, similarly driven by the explosion of telehealth services, Australian authorities have also raised concerns about the lack of oversight and potential for abuse of this model.
In September 2024, the Australian Health Practitioner Regulation Agency (AHPRA) established a new Rapid Regulatory Response Unit (RRRU), tasked with investigating rapidly evolving healthcare models, including online prescriptions for medical cannabis.
This marked a stark shift in its strategy, moving from targeting individual practitioners to investigating systemic issues in its current framework.
Earlier this month, new prescribing data gathered by the regulator uncovered what it called concerning prescribing patterns, raising ‘red flags’ and showing that ‘some practitioners are not meeting their professional obligations’.
This included findings that just eight practitioners had issued more than 10,000 prescriptions over a six-month period, including a single prescriber who issued over 17,000 by themselves.
In response, AHPRA has published new guidance for the medical cannabis sector, warning operators that it will not hesitate to prosecute those who violate these new rules.
AHPRA has already taken action against 57 healthcare practitioners, and is investigating a further 60.
The new AHPRA guidelines require clinics to:
Treat medicinal cannabis like any drug of dependence (e.g. opioids)
Prescribe only when clinically appropriate and not as first-line treatment
Conduct a thorough patient assessment, a treatment plan, and an exit strategy
Reflect clinical need, not patient demand
Models built around single-medicine prescribing are now under review
Future restrictions on direct prescribing by product sponsors are likely
- Unacceptable practices include:
No legitimate indication
Inadequate mental health checks
Ultra-short consults
Conflicts of interest (e.g. prescribing & dispensing)
The post Victim of Its Own Success?: German & Australian Regulators Crackdown on Booming Cannabis Telemedicine Sector appeared first on Business of Cannabis.
Continue reading...
